PMID- 11958741
OWN - NLM
STAT- MEDLINE
DCOM- 20150716
LR  - 20191105
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 30
IP  - 2
DP  - 2002 Mar-Apr
TI  - Omalizumab. A review of the new treatment of allergic asthma and seasonal 
      allergic rhinitis.
PG  - 94-9
AB  - The causal role of immunoglobulin E (IgE) in triggering the cascade of 
      biochemical events leading to allergic disease is well established. Treatments 
      that selectively inhibit IgE activity are a logical approach in managing the 
      allergic response. Omalizumab is a recombinant humanised monoclonal antibody 
      which specifically binds to the Cepsilon3 domain of immunoglobulin (Ig) E, the site of 
      high-affinity IgE receptor binding. The clinical benefit and steroid-sparing 
      effect of treatment with the anti-immunoglobulin-E (IgE) antibody, Omalizumab, 
      was assessed in patients with moderate-to-severe allergic asthma and seasonal 
      allergic rhinitis. Intravenous and subcutaneous administration of anti-IgE mAb 
      reduces circulating levels of IgE in atopic patients to low levels commonly seen 
      in non-atopic individuals. Anti-IgE therapy offers protection against 
      allergen-induced bronchoconstriction, reduces the need for short acting inhaled 
      beta 2-agonist and corticosteroids among asthmatic patients and reduces severity 
      of symptoms of allergic rhinitis. Adverse events were infrequent in clinical 
      trials of omalizumab, and not significantly different from placebo. The most 
      frequent drug-related event was mild to moderate urticaria. They do not induce 
      anaphylaxis and the occurrence of antibodies against anti-IgE mAb is sporadic. 
      The results of cited studies suggest that humanized anti-IgE monoclonal 
      antibodies may have important immunotherapeutic benefit for treatment of allergic 
      disorders.
FAU - Felix Toledo, R
AU  - Felix Toledo R
AD  - Allergy Section. University Hospital Virgen de la Arrixaca, Murcia (Spain).
FAU - Negro Alvarez, J M
AU  - Negro Alvarez JM
FAU - Miralles Lopez, J C
AU  - Miralles Lopez JC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Humans
MH  - Omalizumab
MH  - Rhinitis, Allergic, Seasonal/*drug therapy
EDAT- 2002/04/18 10:00
MHDA- 2015/07/17 06:00
CRDT- 2002/04/18 10:00
PHST- 2002/04/18 10:00 [pubmed]
PHST- 2015/07/17 06:00 [medline]
PHST- 2002/04/18 10:00 [entrez]
AID - 13029071 [pii]
AID - 10.1016/s0301-0546(02)79097-6 [doi]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 2002 Mar-Apr;30(2):94-9. doi: 
      10.1016/s0301-0546(02)79097-6.